LRMR · NASDAQ
Larimar Therapeutics (LRMR) Stock Price & Fundamentals
Larimar Therapeutics (LRMR) closed at $256.01 on Oct 9, 2026, down 0.95% from the previous close of $258.47.
Share price, past year
1Y +5.15%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $256.01 |
| Sep 30, 2026 | $263.40 |
| Aug 31, 2026 | $273.78 |
| Jul 31, 2026 | $278.40 |
| Jun 30, 2026 | $254.73 |
| May 29, 2026 | $257.75 |
| Apr 30, 2026 | $264.15 |
| Mar 31, 2026 | $265.48 |
| Feb 27, 2026 | $253.26 |
| Jan 30, 2026 | $248.06 |
| Dec 31, 2025 | $251.32 |
| Nov 28, 2025 | $246.45 |
| Oct 31, 2025 | $227.38 |
Key statistics
- Market cap
- $26.60B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- −$172.61M
- Shares outstanding
- 103.9M
- Dividend yield
- —
- 52-week range
- $223.76 – $285.41
Larimar Therapeutics's market cap is $26.60B, based on a share price of $256.01 and 103.9M shares outstanding as of Jun 30, 2026.
Financials
Larimar Therapeutics reported revenue of $0.00 for fiscal 2019.
Larimar Therapeutics reported a net loss of $165.67M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2019ended Dec 31, 2019 | $0.00 | — | −$23.13M | — | −$3.80 | −$22.78M |
| FY2018ended Dec 31, 2018 | $0.00 | — | −$61.37M | — | −$1.90 | −$51.60M |
| FY2017ended Dec 31, 2017 | $0.00 | — | −$52.03M | — | −$1.90 | −$43.84M |
| FY2016ended Dec 31, 2016 | $0.00 | — | −$57.88M | — | −$2.12 | −$52.64M |
| FY2015ended Dec 31, 2015 | $0.00 | — | — | — | −$2.78 | — |
| FY2014ended Dec 31, 2014 | $0.00 | — | — | — | — | — |
| FY2013ended Dec 31, 2013 | $0.00 | — | — | — | — | — |
| FY2012ended Dec 31, 2012 | $0.00 | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2020ended Mar 31, 2020 | $0.00 | — | — |
| Q4 FY2019ended Dec 31, 2019 | $0.00 | — | — |
| Q3 FY2019ended Sep 30, 2019 | $0.00 | — | — |
| Q2 FY2019ended Jun 30, 2019 | $0.00 | — | — |
| Q1 FY2019ended Mar 31, 2019 | $0.00 | — | — |
| Q4 FY2018ended Dec 31, 2018 | $0.00 | — | — |
| Q3 FY2018ended Sep 30, 2018 | $0.00 | — | — |
| Q2 FY2018ended Jun 30, 2018 | $0.00 | — | — |
Company profile
- Name
- Larimar Therapeutics, Inc.
- Ticker
- LRMR
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- Three Bala Plaza East. Suite 506, Bala Cynwyd, PA 19004
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001374690
Recent SEC filings
- Sep 29, 2026
- Aug 4, 2026
- Aug 4, 2026
- Jun 29, 2026
- May 19, 2026
- May 14, 2026
- May 14, 2026
- Mar 19, 2026
Frequently asked questions
What is Larimar Therapeutics's stock price?
Larimar Therapeutics (LRMR) closed at $256.01 on Oct 9, 2026, down 0.95% from the previous close of $258.47.
What is Larimar Therapeutics's market cap?
Larimar Therapeutics's market cap is $26.60B, based on a share price of $256.01 and 103.9M shares outstanding as of Jun 30, 2026.
How much revenue does Larimar Therapeutics make?
Larimar Therapeutics reported revenue of $0.00 for fiscal 2019.
Does Larimar Therapeutics pay a dividend?
Larimar Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Larimar Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures